Farmaceutica Remedia (BSE:RMAH) EPS (Basic): lei0.06 (TTM As of Mar. 2026)


BSE:RMAH Farmaceutica Remedia SA BSE:RMAH
60 GF Score
Price lei0.79
GF Value lei0.79
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Farmaceutica Remedia EPS (Basic)?

Farmaceutica Remedia BSE:RMAH -0.25% 60 EPS (Basic) is lei0.06 as of Mar. 2026. GuruFocus rates BSE:RMAH with a GF Score™ of 60/100 and a GF Value™ of lei0.79 (Fairly Valued). The stock has 4 warning signs investors should review.

Farmaceutica Remedia's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was lei0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was lei0.06.

Farmaceutica Remedia's EPS (Diluted) for the three months ended in Mar. 2026 was lei0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was lei0.06.

Farmaceutica Remedia's EPS without NRI for the three months ended in Mar. 2026 was lei0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 0.05.

During the past 12 months, Farmaceutica Remedia's average EPS without NRIGrowth Rate was -13.30% per year. During the past 3 years, the average EPS without NRI Growth Rate was 9.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Farmaceutica Remedia's highest 3-Year average EPS without NRI Growth Rate was 81.70% per year. The lowest was -29.80% per year. And the median was 2.20% per year.

Farmaceutica Remedia  (BSE:RMAH) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Farmaceutica Remedia EPS (Basic) Related Terms

Farmaceutica Remedia EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Farmaceutica Remedia's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farmaceutica Remedia EPS (Basic) Chart

Farmaceutica Remedia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.06 0.08 0.07 0.08

Farmaceutica Remedia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.03 0.01 0.02 0.00
BSE:RMAH
60GF Score
Farmaceutica Remedia SA BSE:RMAH
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Farmaceutica Remedia EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Farmaceutica Remedia's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(8.038-0)/95.465
=0.08

Farmaceutica Remedia's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(0.671-0)/93.703
=0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of lei0.06 mean?
Farmaceutica Remedia (BSE:RMAH) has a EPS (Basic) of lei0.06 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Farmaceutica Remedia and its competitors.
Is Farmaceutica Remedia's EPS (Basic) too high?
Farmaceutica Remedia's current EPS (Basic) is lei0.06. Overall, Farmaceutica Remedia has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's EPS (Basic) compare to MCK and COR?
Farmaceutica Remedia's EPS (Basic) of lei0.06 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Distribution company?
A good EPS (Basic) depends on the Medical Distribution industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Farmaceutica Remedia and its competitors. Farmaceutica Remedia's current EPS (Basic) is lei0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Based on GuruFocus' analysis, Farmaceutica Remedia (BSE:RMAH) is currently considered Fairly Valued. The stock's GF Value™ is lei0.79, compared to a current price of lei0.79 — trading 0.3% below its estimated fair value. The current EPS (Basic) is lei0.06. Farmaceutica Remedia's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Farmaceutica Remedia (BSE:RMAH), the current EPS (Basic) is lei0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Farmaceutica Remedia (BSE:RMAH) Overvalued in 2026?

Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be undervalued. The current stock price of lei0.79 is trading 0.3% below its estimated GF Value™ of lei0.79. GuruFocus considers Farmaceutica Remedia to be Fairly Valued.

Key valuation signals for BSE:RMAH:

  • EPS (Basic): lei0.06
  • GF Value™: lei0.79 vs. price of lei0.79 (0.3% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the BSE:RMAH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Farmaceutica Remedia Business Description

Address No. 2 Nicolae Balcescu Boulevard, Hunedoara County, Deva, ROU, 330040
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
60GF Score

Get the complete analysis for BSE:RMAH

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei0.79
Price
lei0.79
GF Value